Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963045 | 0.94 | MEN1 (0.42) | MEN1CYP2C9KMT2AALDH1A1AKR1C1 | |
| Formic Acid Methyl Ester SCHEMBL27670593 | 0.84 | GRIN1 (0.35) | MEN1CYP2C9KMT2AALDH1A1AKR1C1 | |
| SCHEMBL4447105 | 0.77 | MEN1 (0.41) | MEN1CYP2C9KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5911749 | 0.77 | MEN1 (0.50) | MEN1CYP2C9KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5253993 | 0.76 | CCR2 (0.49) | KMT2AALDH1A1OPRM1OPRK1CCR2 | |
| SCHEMBL3666780 | 0.75 | MEN1 (0.47) | MEN1CYP2C9KMT2AALDH1A1AKR1C1 | |
| SCHEMBL11465156 | 0.74 | MEN1 (0.38) | MEN1CYP2C9KMT2AALDH1A1MMP2 | |
| SCHEMBL6684432 | 0.74 | KDM1A (0.39) | MEN1CYP2C9KMT2AALDH1A1 | |
| SCHEMBL24581636 | 0.73 | HSD11B1 (0.37) | MEN1CYP2C9KMT2AALDH1A1HSD11B1 | |
| SCHEMBL10257407 | 0.73 | HSD11B1 (0.37) | MEN1CYP2C9KMT2AALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225750-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076629-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076629-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-105646156-B | The method for being used to prepare phenol | 埃克森美孚化学专利公司 | 2018-07-13 | — | — | CN | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| CN-103097331-B | Process for producing phenol | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-01-27 | — | — | CN | disclosed |
| CN-100398524-C | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists | ROCHE PALO ALTO LLC (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1835931-A | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists | ROCHE PALO ALTO LLC (CH) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MEN1 4707/4885CYP2C9 4724/4885KMT2A 4643/4885 |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | MEN1 438/4885CYP2C9 523/4885KMT2A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.